Publications by authors named "W R Burack"
Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.
View Article and Find Full Text PDFArticle Synopsis
- Primary large B-cell lymphomas (IP-LBCLs) occur in "immune-privileged" areas like the CNS, vitreoretina, and testes, where the immune response is weaker.
- These lymphomas typically have a poor prognosis with high chances of returning either at the same spot or another similar site.
- The case discussed features a man with two separate cases of LBCL in the CNS and testis, diagnosed over ten years apart, that were not genetically linked, indicating they were not the same type of cancer.
Article Synopsis
- Classic Hodgkin Lymphoma (cHL) is characterized by the presence of rare malignant HRS cells within a dense T-cell rich immune environment, with approximately 25% of cases linked to the Epstein-Barr Virus (EBV).
- Using advanced imaging techniques, researchers analyzed 20 cHL samples to identify key differences in the tumor microenvironment between EBV-positive and EBV-negative cases, noting variations in T-cell populations and their dysfunction.
- The study highlights distinct transcriptomic profiles that affect HRS cell growth and T-cell interactions, emphasizing the importance of understanding virus-associated tumors for developing targeted therapies.
To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States.
View Article and Find Full Text PDF